John Loper
Friday, April 7, 2017
Apr 7 Cardiology News
Cost effects of risk-factor management in AF, apixaban costs vs warfarin, bioresorbable-scaffold woes, exercise as heart-failure therapy, and surgical left atrial appendage closure are discussed.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment